<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21498658</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>09</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-0111</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>80</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular pharmacology</Title>
                <ISOAbbreviation>Mol. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2',3'-o-(N-methylanthraniloyl)-inosine 5'-triphosphate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>87-96</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1124/mol.111.071894</ELocationID>
            <Abstract>
                <AbstractText>2',3'-O-(N-Methylanthraniloyl)-ITP (MANT-ITP) is the most potent inhibitor of mammalian membranous adenylyl cyclase (mAC) 5 (AC5, K(i), 1 nM) yet discovered and surpasses the potency of MANT-GTP by 55-fold (J Pharmacol Exp Ther 329:1156-1165, 2009). AC5 inhibitors may be valuable drugs for treatment of heart failure. The aim of this study was to elucidate the structural basis for the high-affinity inhibition of mAC by MANT-ITP. MANT-ITP was a considerably more potent inhibitor of the purified catalytic domains VC1 and IIC2 of mAC than MANT-GTP (K(i), 0.7 versus 18 nM). Moreover, there was considerably more efficient fluorescence resonance energy transfer between Trp1020 of IIC2 and the MANT group of MANT-ITP compared with MANT-GTP, indicating optimal interaction of the MANT group of MANT-ITP with the hydrophobic pocket. The crystal structure of MANT-ITP in complex with the G(s)α- and forskolin-activated catalytic domains VC1:IIC2 compared with the existing MANT-GTP crystal structure revealed only subtle differences in binding mode. The higher affinity of MANT-ITP to mAC compared with MANT-GTP is probably due to fewer stereochemical constraints upon the nucleotide base in the purine binding pocket, allowing a stronger interaction with the hydrophobic regions of IIC2 domain, as assessed by fluorescence spectroscopy. Stronger interaction is also achieved in the phosphate-binding site. The triphosphate group of MANT-ITP exhibits better metal coordination than the triphosphate group of MANT-GTP, as confirmed by molecular dynamics simulations. Collectively, the subtle differences in ligand structure have profound effects on affinity for mAC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hübner</LastName>
                    <ForeName>Melanie</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dixit</LastName>
                    <ForeName>Anshuman</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mou</LastName>
                    <ForeName>Tung-Chung</ForeName>
                    <Initials>TC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lushington</LastName>
                    <ForeName>Gerald H</ForeName>
                    <Initials>GH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pinto</LastName>
                    <ForeName>Cibele</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gille</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Geduhn</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>König</LastName>
                    <ForeName>Burkhard</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sprang</LastName>
                    <ForeName>Stephen R</ForeName>
                    <Initials>SR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seifert</LastName>
                    <ForeName>Roland</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 DK046371</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R56 DK046371</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DK46371</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>04</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Pharmacol</MedlineTA>
            <NlmUniqueID>0035623</NlmUniqueID>
            <ISSNLinking>0026-895X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000067956">Adenylyl Cyclase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0237V2ONZJ</RegistryNumber>
                <NameOfSubstance UI="C561028">2',3'-O-(N-methylanthraniloyl)inosine 5'-triphosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>132-06-9</RegistryNumber>
                <NameOfSubstance UI="D007293">Inosine Triphosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.6.1.1</RegistryNumber>
                <NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000067956" MajorTopicYN="Y">Adenylyl Cyclase Inhibitors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007293" MajorTopicYN="N">Inosine Triphosphate</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21498658</ArticleId>
            <ArticleId IdType="pii">mol.111.071894</ArticleId>
            <ArticleId IdType="doi">10.1124/mol.111.071894</ArticleId>
            <ArticleId IdType="pmc">PMC3127541</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Biol Chem. 2003 Mar 7;278(10):7822-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12499374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci STKE. 2007 Nov 20;2007(413):pe64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18029912</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2003 Apr 11;278(15):12672-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12566433</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioorg Med Chem. 2007 Apr 15;15(8):2993-3002</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17329110</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharmacol. 2006 Sep;70(3):878-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16766715</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Sci. 2009 Mar;109(3):354-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19270422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharmacol. 1999 Aug;56(2):348-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10419554</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Phys Chem. 2000;51:129-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11031278</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Pharmacol. 2005 Dec 19;71(1-2):89-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16271707</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2005 Feb 25;280(8):7253-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15591060</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Angew Chem Int Ed Engl. 2002 Aug 2;41(15):2644-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12203463</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Neurochem. 2008 Oct;107(1):105-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18673448</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharmacol. 2009 Mar;75(3):693-703</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19056899</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharmacol. 1998 Aug;54(2):231-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9687563</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2007 May;321(2):608-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17284671</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Comput Chem. 2005 Dec;26(16):1781-802</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16222654</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2009 Jun;329(3):1156-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19307450</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2004 Apr 2;279(14):13317-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14699161</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2009 Sep;330(3):687-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19494187</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Methods Enzymol. 1997;278:363-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9170323</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):141-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14654999</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Methods Enzymol. 1997;276:307-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27754618</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2011 Jan;336(1):104-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20962032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Naunyn Schmiedebergs Arch Pharmacol. 2011 Jun;383(6):573-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21484439</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochemistry. 1989 Jun 13;28(12):4948-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2765520</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2004 May 7;279(19):19955-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14981084</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15299374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15572765</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1997 Dec 12;278(5345):1907-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9417641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Methods Enzymol. 2002;345:198-206</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11665605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Pharmacol Toxicol. 1996;36:461-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8725398</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 1983 Feb 15;742(3):496-508</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6132622</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>